1-2 of 2
Ursula Berger
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Prognostic Impact of Proteolytic Factors (Urokinase-Type Plasminogen Activator, Plasminogen Activator Inhibitor 1, and Cathepsins B, D, and L) in Primary Breast Cancer Reflects Effects of Adjuvant Systemic Therapy

Nadia Harbeck, Uta Alt, Ursula Berger, Achim Krüger, Christoph Thomssen, Fritz Jänicke, Heinz Höfler, Ronald E. Kates, Manfred Schmitt
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (9): 2757–2764.
Published: 01 September 2001
View article titled, Prognostic Impact of Proteolytic Factors (Urokinase-Type Plasminogen Activator, Plasminogen Activator Inhibitor 1, and Cathepsins B, D, and L) in Primary Breast Cancer Reflects Effects of Adjuvant Systemic Therapy
Open the PDF for Prognostic Impact of Proteolytic Factors (Urokinase-Type Plasminogen Activator, Plasminogen Activator Inhibitor 1, and Cathepsins B, D, and L) in Primary Breast Cancer Reflects Effects of Adjuvant Systemic Therapy in another window
Journal Articles

Increased Expression of Matrix Metalloproteinases (MMP)-2, MMP-9, and the Urokinase-Type Plasminogen Activator Is Associated with Progression from Benign to Advanced Ovarian Cancer

Barbara Schmalfeldt, Dieter Prechtel, Kathrin Härting, Kerstin Späthe, Stefan Rutke, Elisabeth Konik, Rafael Fridman, Ursula Berger, Manfred Schmitt, Walther Kuhn, Ernst Lengyel
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (8): 2396–2404.
Published: 01 August 2001
View article titled, Increased Expression of Matrix Metalloproteinases (MMP)-2, MMP-9, and the Urokinase-Type Plasminogen Activator Is Associated with Progression from Benign to Advanced Ovarian Cancer
Open the PDF for Increased Expression of Matrix Metalloproteinases (MMP)-2, MMP-9, and the Urokinase-Type Plasminogen Activator Is Associated with Progression from Benign to Advanced Ovarian Cancer in another window